BUSINESS WIRE: Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

HEIDELBERG, Germany --(BUSINESS WIRE)-- 31.05.2023 --

Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.

Details of the poster presentation are as follows:

Title: Early detection of lung cancer using small RNAs
Presenting Author: Bruno Steinkraus, PhD, Chief Scientific Officer of Hummingbird Diagnostics
Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Abstract: #3035
Poster Board: #233
Location: Hall A
Date/Time: June 3, 2023 from 8:00 AM – 11:00 AM CDT

About Hummingbird Diagnostics GmbH

Hummingbird is harnessing the predictive power of blood-borne small RNAs to provide insights into human health and disease. Analyzing small RNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies. To learn more, visit: https://www.hummingbird-diagnostics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005391/en/

Media:
MacDougall Advisors
Karen Sharma
ksharma@macdougall.bio